Catalyst Pharmaceuticals Inc
Research Catalyst Pharmaceuticals Inc (CPRX) on Bullrun: market cap USD 3.85B, P/E 18.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCPRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.85B
- P/E18.1
- Financial periodQ1 2026
- RevenueUSD 149.39M
- Net incomeUSD 63.73M
- Free cash flowUSD 208.13M
- Gross margin343.5%
Valuation Snapshot
latest market cap is USD 3.85B; P/E is 18.1.
Peer valuation comparison
Latest P/E is 18.1x versus a Healthcare sector median of 24.46x (26.0% below).
Latest P/E is 18.1x versus a United States median of 24.87x (27.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 588.99M | USD 214.33M | USD 208.61M | 85.2% | 1.68 | USD 709.17M | USD 2.79M | USD 954.27M |
| FY2024 | USD 491.73M | USD 163.89M | USD 239.25M | 86.0% | 1.31 | USD 517.55M | USD 3.19M | USD 727.63M |
| FY2023 | USD 398.20M | USD 71.41M | USD 143.37M | 86.9% | 0.63 | USD 137.64M | USD 3.56M | USD 387.88M |
| FY2022 | USD 214.20M | USD 83.08M | USD 116.02M | 83.9% | 0.75 | USD 298.40M | USD 4.05M | USD 300.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-21 | USD 3.85B | 18.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.86B | 13.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.52B | 15.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.79B | 31.7 | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.94B | 30.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 697.26M | 18.3 | n/a | n/a |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Catalyst Pharmaceuticals Inc's market cap?
Catalyst Pharmaceuticals Inc's market capitalization is USD 3.85B.
What is Catalyst Pharmaceuticals Inc's P/E ratio?
Catalyst Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 18.1.
What does Catalyst Pharmaceuticals Inc do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.